FDA Approved Gene Therapy List for Rare Disease

Key Takeaways

• FDA granted accelerated approval to Kresladi (marnetegragene autotemcel) on March 26, 2026 for pediatric severe LAD-I without an HLA-matched sibling donor.
• Casgevy and Lyfgenia, approved December 8, 2023, remain the landmark sickle-cell gene therapies and Casgevy is the first FDA-approved CRISPR/Cas9 product.
• An FDA approved gene therapy list is product-specific: indication, age, vector class, and confirmatory-trial obligations differ by BLA.
• Unverified “cure rate” percentages and wholesale prices should not be cited unless they appear on FDA or peer-reviewed primary pages.

What is on the current FDA approved gene therapy list?

FDA licenses cellular and gene therapy products through CBER biologics applications. For rare disease diligence, treat each product page as the source of truth for proper name, tradename, manufacturer, and indication.

Recent rare-disease anchors include Kresladi (marnetegragene autotemcel) for severe LAD-I and the December 2023 sickle-cell pair Casgevy and Lyfgenia. Broader oncology CAR-T products also appear on FDA biologics lists, but they are separate from classic in vivo AAV or rare-immunodeficiency autologous HSC gene therapies.

Why does the March 2026 Kresladi approval matter?

FDA’s March 26, 2026 press announcement states Kresladi is the first gene therapy for severe Leukocyte Adhesion Deficiency Type I. The product uses autologous hematopoietic stem cells modified to introduce functional ITGB2 copies, then infused after conditioning.

FDA granted accelerated approval to Rocket Pharmaceuticals, Inc., with post-approval studies required to verify clinical benefit. That distinction matters for investors: accelerated approval is not the same as traditional approval with confirmatory evidence already complete.

Which sickle cell gene therapies sit on the FDA list?

On December 8, 2023, FDA approved Casgevy and Lyfgenia for sickle cell disease in patients 12 years and older. Casgevy uses CRISPR/Cas9 genome editing of patient hematopoietic stem cells. Lyfgenia uses a lentiviral vector to produce HbAT87Q hemoglobin.

• Both received Priority Review, Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy designations.
• Casgevy was also later positioned for transfusion-dependent beta-thalassemia in separate labeling updates tracked on FDA product pages.
• Manufacturing and center-of-excellence capacity, not just the BLA stamp, often pace real-world uptake.

How should BD teams use an FDA approved gene therapy list?

Build a working list with four columns: BLA/tradename, exact indication text, approval pathway (traditional vs accelerated), and confirmatory commitments. Pull indication language from FDA product pages, not secondary blogs.

For competitive intelligence, pair the list with trial identifiers on ClinicalTrials.gov when sponsors disclose confirmatory studies. Do not assume every rare-disease gene therapy is one-and-done dosing, durable, or reimbursed at a stated list price unless those facts appear in primary sources.

What remains unproven after recent rare-disease gene therapy approvals?

Accelerated approval for Kresladi explicitly requires post-approval studies to verify benefit. Long-term durability, secondary malignancy risk for integrating vectors, and real-world manufacturing success rates are not fully settled in public FDA announcements for every product.

Secondary websites often publish price tables and “complete lists” without FDA timestamps. If a figure is missing from FDA or a peer-reviewed primary paper, delete it from investor materials.

Approval pathway differences investors should track

Traditional approval, accelerated approval, and label expansions create different catalyst calendars. Casgevy’s CRISPR first-in-class status in 2023 and Kresladi’s 2026 LAD-I accelerated approval show FDA will license transformative modalities for ultra-rare diseases when surrogate endpoints are judged reasonably likely to predict benefit.

Watch for Rare Pediatric Disease Priority Review Vouchers, confirmatory trial timelines, and manufacturing inspection outcomes. Those events move valuation more than generic “gene therapy momentum” narratives.

Related NovaPharma coverage

• FDA Approves First CRISPR Gene Therapy for Sickle Cell Disease
• FDA gene therapy guidance: Industry-friendly draft for BD
• $2M Gene Therapy Cures Need a Financing Model

Frequently Asked Questions

Primary Sources

1. FDA: Approves first gene therapy for severe LAD-I (Kresladi)
2. FDA: Kresladi product page (BLA 125806)
3. FDA: Approves Casgevy and Lyfgenia for sickle cell disease
4. ClinicalTrials.gov registry (confirmatory and supporting trials)